Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SAT1 | P21673 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.46 |
| ▸ | ADH1B | P00325 | 1/20 | 0.46 |
| ▸ | ADH1C | P00326 | 1/20 | 0.46 |
| ▸ | ADH1A | P07327 | 1/20 | 0.46 |
| ▸ | ADH4 | P08319 | 1/20 | 0.46 |
| ▸ | ADH7 | P40394 | 1/20 | 0.46 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.42 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL332965 | 1.00 | SAT1 (0.60) | SAT1TSHRALDH1A1EPHX1ADH1B | |
| SCHEMBL4424094 | 1.00 | SAT1 (0.60) | SAT1TSHRALDH1A1EPHX1ADH1B | |
| SCHEMBL27896724 | 1.00 | SAT1 (0.60) | SAT1TSHRALDH1A1EPHX1ADH1B | |
| SCHEMBL6832121 | 1.00 | SAT1 (0.60) | SAT1TSHRALDH1A1EPHX1ADH1B | |
| SCHEMBL333465 | 1.00 | SAT1 (0.60) | SAT1TSHRALDH1A1EPHX1ADH1B | |
| SCHEMBL333040 | 1.00 | SAT1 (0.60) | SAT1TSHRALDH1A1EPHX1ADH1B | |
| SCHEMBL332482 | 1.00 | SAT1 (0.60) | SAT1TSHRALDH1A1EPHX1ADH1B | |
| SCHEMBL333304 | 1.00 | SAT1 (0.60) | SAT1TSHRALDH1A1EPHX1ADH1B | |
| SCHEMBL9348906 | 1.00 | SAT1 (0.60) | SAT1TSHRALDH1A1EPHX1ADH1B | |
| Hydrochloric Acid SCHEMBL25309116 | 0.98 | SAT1 (0.58) | SAT1TSHRALDH1A1EPHX1ADH1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2531181-A1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | Pharma Two B Ltd. (IL) | 2012-12-12 | — | — | EP | claimed |
| US-20120301542-A1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | PHARMA TWO B LTD. (IL) | 2012-11-29 | — | — | US | claimed |
| CN-102791258-A | Extended release formulations of rasagiline and uses thereof | PHARMA TWO B LTD | 2012-11-21 | — | — | CN | claimed |
| WO-2011095973-A1 | EXTENDED RELEASE FORMULATIONS OF RASAGILINE AND USES THEREOF | PHARMA TWO B LTD. (IL) | 2011-08-11 | — | — | WO | claimed |
| EP-1686973-A4 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES | TECHNION RES & DEV FOUNDATION (IL) | 2009-03-25 | — | — | EP | claimed |
| EP-1942881-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL FAILURE | Technion Research and Development of Foundation, Ltd. (IL) | 2008-07-16 | — | — | EP | claimed |
| US-20080090915-A1 | METHOD FOR PREVENTING OR ATTENUATING ANTHRACYCLINE-INDUCED CARDIOTOXICITY | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2008-04-17 | — | — | US | claimed |
| WO-2007039909-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF RENAL FAILURE | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2007-04-12 | — | — | WO | claimed |
| US-20070082958-A1 | Methods for treatment of renal failure | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2007-04-12 | — | — | US | claimed |
| US-20060287401-A1 | Methods for treatment of cardiovascular disorders and diseases | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2006-12-21 | — | — | US | claimed |
| EP-1686973-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION, LTD. (IL) | 2006-08-09 | — | — | EP | claimed |
| US-20050171210-A1 | Compositions and methods for treatment of cardiovascular disorders and diseases | TECHNION RESEARCH AND DEVELOPMENT FOUNDATION LTD. (IL) | 2005-08-04 | — | — | US | claimed |
| WO-2005051371-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES | TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (IL) | 2005-06-09 | — | — | WO | claimed |
| US-6809120-B1 | PROTECTING NORMAL CELLS; OVERCOMING DRUG RESISTANCE AND/OR TOXICITY | UNIVERSITY OF SASKATCHEWAN TECHNOLOGIES INC. (CA) | 2004-10-26 | — | — | US | claimed |
| EP-0996612-B1 | ALIPHATIC PROPARGYLAMINES AS CELLULAR RESCUE AGENTS | UNIV SASKATCHEWAN (CA) | 2003-04-09 | — | — | EP | claimed |
| US-6251950-B1 | ADMINISTERING TO THE PATIENT AN ALIPHATIC-PROPARGYLAMINE OR SALT FOR THE TREATMENT OF ACUTE AND CHRONIC DISEASES IN WHICH CELL DEATH OCCURS BY APOPTOSIS OR FOR THE TREATMENT OF PREMATURE DEGENERATION OF CELLS IN MAMMALS | UNIVERSITY OF SASKATCHEWAN (CA) | 2001-06-26 | — | — | US | claimed |
| EP-0996612-A2 | ALIPHATIC PROPARGYLAMINES AS CELLULAR RESCUE AGENTS | University of Saskatchewan Technologies Inc. (CA) | 2000-05-03 | — | — | EP | claimed |
| WO-1999003817-A2 | ALIPHATIC PROPARGYLAMINES AS CELLULAR RESCUE AGENTS | UNIVERSITY OF SASKATCHEWAN TECHNOLOGIES INC. (CA) | 1999-01-28 | — | — | WO | claimed |
| US-20230145782-A1 | p53 MODULATORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-05-11 | — | — | US | disclosed |
| US-5840979-A | USEFUL IN THE TREATMENT AND PREVENTION OF DISEASES IN WHICH CELL DEATH OCCURS BY APOPTOSIS | UNIVERSITY OF SASKATCHEWAN (CA) | 1998-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145782-A1 | p53 MODULATORS AND USES THEREOF | TP53, TP53BP1, MDM2 | SAT1 4021/4885TSHR 4196/4885ALDH1A1 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.